Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Zealand Pharma will participate in the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022. CEO Adam Steensberg and CFO Matthew Dallas will present at 9:30 a.m. EST. A live webcast will be available on Zealand’s website, with a replay archived post-presentation. Zealand is focused on peptide-based medicines, having advanced over 10 drug candidates into clinical development, including two on the market and three in late-stage development. With collaborations with Boehringer Ingelheim and AstraZeneca, Zealand aims to enhance patient access to its innovative therapies.
Zealand Pharma announces the appointment of Dr. Adam Steensberg as the new Chief Executive Officer as of March 30, 2022. The company is refocusing its strategy to prioritize research and development while restructuring its commercial operations, aiming for a 35% reduction in annual operating expenses from 2021 levels. Zealand plans to maximize the value of its products Zegalogue and V-Go through strategic partnerships. The company has updated its financial guidance, revising net operating expenses for 2022 to DKK 1,000 million +/-10% and net product revenue to DKK 115 million +/-10%.
Summary not available.
On March 10, 2022, Zealand Pharma A/S announced its Annual General Meeting set for April 6, 2022, to be held electronically. Key agenda items include approval of the audited Annual Report for 2021, covering a loss of TDKK 1,018,149, and proposals for Board elections and remuneration policy amendments. Shareholder authorizations will also be sought for treasury share acquisitions and convertible debt issuance, with the proposed capital increases capped at DKK 10,850,136. Participation requires prior online registration due by April 4, 2022.
Zealand Pharma has reported significant advancements in its clinical pipeline for 2021, including FDA approval for Zegalogue (dasiglucagon) and progress in multiple trials for glepaglutide and dasiglucagon. Financially, Zealand generated DKK 292.6 million in revenue, down from DKK 353.3 million in 2020, while net operating expenses rose to DKK 1,224.7 million. The company anticipates product revenue of DKK 235 million in 2022. Zealand's pipeline includes new therapies for obesity, diabetes, and rare diseases, bolstered by a $200 million financing agreement with Oberland Capital.
Zealand Pharma will host a conference call on March 10, 2022, at 4 PM CET (10 AM ET) to discuss its full-year results for 2021. Key executives, including President and CEO Emmanuel Dulac, will present and engage in a Q&A session. Interested participants can connect via dial-in numbers provided for various regions, including the U.S. and Europe. A live audio webcast of the call will be available on Zealand's investor website, along with a recording and transcript post-event. Zealand Pharma focuses on innovative peptide-based medicines.
Zealand Pharma (NASDAQ: ZEAL) announced on February 25, 2022, that major shareholder The Capital Group Companies now holds 4.89% of Zealand's voting rights and share capital. This notification follows the requirements of the Danish Capital Markets Act. Additionally, SMALLCAP World Fund, Inc., a fund managed by Capital Group, has also reported the same holding percentage. Zealand Pharma focuses on innovative peptide-based medicines, with marketed products including V-Go® and Zegalogue®.
Zealand Pharma has successfully completed enrollment in its Phase 3 trial (17103) of dasiglucagon for treating Congenital Hyperinsulinism (CHI) in children under 12 months. This milestone marks the largest clinical development program for CHI. Top-line results are anticipated in Q2 2022, and if favorable, the company plans to seek FDA marketing approval based on data from both Phase 3 trials. CHI causes severe hypoglycemia, necessitating constant monitoring. Dasiglucagon aims to reduce hospital visits and improve treatment outcomes for affected children.
Zealand Pharma has successfully completed patient enrollment in its pivotal EASE-SBS 1 Phase 3 trial for glepaglutide, a treatment for Short Bowel Syndrome (SBS). Originally set for 129 patients, the sample size is now approximately 108 due to challenges from COVID-19. Full results are anticipated in the third quarter of 2022, with potential filing for FDA marketing approval pending positive outcomes. The trial has also maintained statistical power with no interim analysis needed, enhancing the credibility of results. Glepaglutide has received Orphan Drug Designation from the FDA.
Zealand Pharma has announced that The Capital Group Companies now holds 5.61% of its voting rights, as per the Danish Capital Markets Act. This notification follows a change in the total holding of voting rights and financial instruments by the shareholder.
Zealand operates in the biotechnology sector, focusing on developing peptide-based medicines with various candidates in clinical development, including partnerships with Boehringer Ingelheim and AstraZeneca.